Pet Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type (Canine, Feline, Equine), By Vaccination (Canine Family, Feline Family, Others), By Mode Of Administration (Injectable Vaccines, Intranasal Vaccines), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.14 Billion
CAGR (2026-2031)	6.31%
Fastest Growing Segment	Oral
Largest Market	North America
Market Size (2031)	USD 3.09 Billion

Market Overview

The Global Pet Vaccine Market will grow from USD 2.14 Billion in 2025 to USD 3.09 Billion by 2031 at a 6.31% CAGR. Pet vaccines are biological preparations designed to stimulate a companion animal's immune system, thereby producing antibodies to provide immunity against specific viral, bacterial, and parasitic diseases. The market is primarily propelled by the rising prevalence of zoonotic threats and a substantial increase in global pet adoption, which necessitates consistent preventative veterinary care. Furthermore, stringent government mandates regarding rabies control and the growing humanization of pets encourage higher compliance with immunization protocols among owners. According to Animal Medicines Australia, in 2025, 73% of Australian households owned a pet, illustrating the robust ownership rates that underpin the demand for veterinary biologicals in developed markets.

However, market expansion is frequently impeded by the escalating cost of veterinary services, which creates financial barriers for price-sensitive pet owners. High expenses associated with routine wellness examinations and vaccine administration often lead to deferred treatment or non-compliance with annual booster schedules. This affordability constraint, coupled with logistical complexities in maintaining cold-chain integrity during distribution to remote areas, remains a significant hurdle to the consistent broadening of the global pet vaccine industry.

Key Market Drivers

The Increasing Humanization of Companion Animals is a primary catalyst for market growth, significantly influencing the demand for preventative healthcare products and compliance with immunization schedules. As owners increasingly view their animals as integral family members, they are more inclined to prioritize longevity and quality of life, leading to higher adherence to strict vaccination protocols against viral and bacterial threats. This cultural shift effectively expands the addressable market for biologicals by ensuring that a larger proportion of the pet population receives routine care. Evidence of this robust ownership base is substantial; according to UK Pet Food, March 2024, in the 'Pet Data Report 2024', the total pet population in the United Kingdom reached 36 million, underscoring the vast volume of companion animals requiring consistent veterinary attention.

Concurrently, the Escalating Expenditure on Veterinary Healthcare bolsters the market by facilitating the adoption of premium and novel vaccine formulations. The rising willingness of pet owners to allocate significant financial resources toward medical services counteracts potential cost barriers, driving value growth within the sector. According to the American Pet Products Association, March 2025, in the 'State of the Industry 2025' report, annual spending on veterinary care and product sales in the United States was projected to reach $41.4 billion, reflecting the high priority placed on animal wellness. This financial commitment is further supported by strong engagement with veterinary professionals; according to Animal Medicines Australia, September 2025, in the 'Pets in Australia 2025' report, 89% of dogs and 75% of cats had visited a veterinarian in the preceding year, demonstrating the high compliance rates that underpin recurring revenue for vaccine manufacturers.

Download Free Sample Report

Key Market Challenges

The escalating cost of veterinary services stands as a primary impediment to the growth of the global pet vaccine market. As the financial burden of routine animal healthcare rises, price-sensitive pet owners are increasingly forced to prioritize urgent medical interventions over preventative measures such as vaccination. This economic strain directly disrupts the continuity of care required for effective immunization protocols, leading to a reduction in the overall volume of vaccines administered. When wellness examinations become prohibitively expensive, owners frequently defer these critical visits, resulting in missed opportunities for veterinarians to administer necessary annual booster shots and maintain up-to-date immunity levels.

Consequently, this trend of deferred maintenance creates a direct contraction in market demand. The inability of owners to sustain recommended immunization schedules weakens herd immunity and stagnates revenue streams for vaccine manufacturers. According to the American Veterinary Medical Association, in 2025, veterinary service prices increased by 5.7 percent, which coincided with a 3 percent decline in patient visits year-over-year. This correlation between rising costs and reduced clinic footfall demonstrates how affordability constraints materially hamper the industry's ability to maintain consistent growth rates across both developed and developing regions.

Key Market Trends

The Commercialization of Therapeutic Vaccines for Chronic Diseases is fundamentally altering the Global Pet Vaccine Market by expanding the scope of immunization from infectious disease prevention to the active treatment of complex, non-infectious conditions like oncology. Manufacturers are increasingly leveraging autologous and precision immunotherapy technologies to create biologicals that stimulate a companion animal's immune system to target tumor-specific antigens. This clinical evolution provides veterinarians with viable interventions for terminal diagnoses that previously had limited options. For instance, according to Torigen Pharmaceuticals, February 2025, in the 'New Hope For Pets In The Fight Against Cancer' press release, dogs with metastatic hemangiosarcoma treated with the company's targeted autologous cancer vaccine demonstrated a 3.5x increase in overall survival compared to those treated with surgery alone. This improved efficacy validates the growing reliance on therapeutic biologicals to manage chronic health issues in aging pet populations.

Concurrently, the Transition to Recombinant and Subunit Vaccine Platforms is reshaping the industry's manufacturing landscape as companies move away from traditional live-attenuated methods to enhance safety and production scalability. This trend prioritizes the development of high-purity antigens and large-molecule biologicals, necessitating substantial capital improvements in bioprocessing infrastructure to ensure supply chain resilience. This strategic shift toward advanced platform technologies is evident in major industrial investments; according to Merck Animal Health, May 2025, in a press release regarding facility enhancements, the company announced an allocation of $895 million to expand its De Soto, Kansas manufacturing site specifically to increase the production capacity of large molecule vaccines and biologics. Such investments underscore the market's commitment to sophisticated delivery platforms that offer superior potency and reduced risk of adverse events for companion animals.

Segmental Insights

The Oral segment represents the fastest-growing category in the Global Pet Vaccine Market, primarily driven by the increasing demand for non-invasive administration methods that minimize stress for companion animals and owners. This expansion is further supported by the logistical advantages of oral formulations, which simplify distribution for mass immunization initiatives. A notable development validation this trend is the USDA approval of advanced oral vaccines, such as Merck Animal Health’s Nobivac Intra-Trac Oral BbPi. These innovations effectively target mucosal immunity while offering a convenient alternative to traditional injectables, thereby accelerating the segment’s adoption globally.

Regional Insights

North America maintains a dominant position in the global pet vaccine market, driven by high rates of pet ownership and increased expenditure on animal healthcare. The region benefits from a well-established veterinary infrastructure that facilitates accessible preventive treatments. Additionally, stringent regulatory frameworks enforced by agencies such as the United States Department of Agriculture ensure the safety and efficacy of veterinary biologics, fostering consumer trust. The concentrated presence of major pharmaceutical manufacturers further strengthens the local supply chain, ensuring consistent availability of essential immunization products across the region.

Recent Developments

• In March 2025, Zoetis announced the launch of a new formulation of its Vanguard B Intranasal vaccine, offering optimized protection for dogs against Bordetella bronchiseptica, a primary cause of kennel cough. The updated vaccine features a reduced 0.5 mL dose volume and allows for single-nostril administration, significantly improving the vaccination experience for both veterinarians and pets, particularly puppies as young as three weeks old. This product development focuses on enhancing compliance and comfort without compromising efficacy. The launch reinforces the company's commitment to advancing respiratory protection standards within the competitive companion animal vaccine sector.
• In September 2024, Boehringer Ingelheim completed the acquisition of Saiba Animal Health, a Swiss company specializing in the development of therapeutic vaccines. This strategic move was designed to expand Boehringer Ingelheim's research capabilities in treating chronic diseases in pets, such as osteoarthritis, atopic dermatitis, and chronic kidney disease, using virus-like particle (VLP) technology. Unlike traditional vaccines that prevent infectious diseases, these innovative therapeutic vaccines aim to induce an immune response against the host's own disease-causing proteins. This acquisition reflects a growing industry trend towards developing novel immunotherapies for managing long-term health conditions in companion animals.
• In July 2024, Elanco Animal Health entered into a strategic partnership with The Veterinary Cooperative, the largest purchasing cooperative for independent veterinary practices in the United States. This collaboration was established to provide member clinics with enhanced access to Elanco's comprehensive portfolio of animal health solutions, including its range of vaccines, parasiticides, and therapeutics. The agreement aimed to support independent veterinarians by offering exclusive savings and educational resources, thereby enabling these practices to maintain competitive standards of care. This partnership highlights the importance of distribution channels and commercial collaborations in strengthening market presence.
• In June 2024, Merck Animal Health announced the United States Department of Agriculture (USDA) approval of NOBIVAC NXT Canine Flu H3N2, a significant advancement in the Global Pet Vaccine Market. This product represents the first canine influenza vaccine to utilize the company's proprietary RNA-particle technology, which allows for a precise immune response against the H3N2 virus strain. The vaccine is designed as a nonadjuvanted, low-volume 0.5 mL dose, intended to improve comfort and safety for dogs while inducing robust immunity. This launch underscores the industry's shift towards advanced biotechnological platforms for companion animal disease prevention.

Key Market Players

• Zoetis Inc.
• Bioveta a.s
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac S.A.
• Zendal Group
• Elanco Animal Health Incorporated

By Animal Type	By Vaccination	By Mode Of Administration	By Region
Canine Feline Equine	Canine Family Feline Family Others	Injectable Vaccines Intranasal Vaccines	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pet Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pet Vaccine Market , By Animal Type:

• Canine
• Feline
• Equine

• Pet Vaccine Market , By Vaccination:

• Canine Family
• Feline Family
• Others

• Pet Vaccine Market , By Mode Of Administration:

• Injectable Vaccines
• Intranasal Vaccines

• Pet Vaccine Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE